Department of Pneumology, Mainz University Medical Center and Department of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany
Michael Kreuter is Professor of Pulmonology at the University of Mainz, Germany and Director of the Mainz Center for Pulmonary Medicine, which is an expert lung center consisting of the Departments of Pneumology, Mainz University Medical Center and of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany. Formerly, he has been working that the University of Heidelberg as Director of the center for interstitial and rare lung diseases and was Director of the Clinic for Pneumology at the RKH Clinic Germany. Currently, he serves the European Respiratory Society (ERS) as secretary of the ILD assembly and is engaged in several patient support groups.
Professor Kreuter is board certified in Internal Medicine, Pulmonology and Haematology-Oncology. He completed a clinical fellowship in Muenster, Germany, and a research fellowship at Harvard Medical School, Boston, USA. From 2005 to 2023 he has been working at the Chest Clinic of the University of Heidelberg and in 2023 he accepted a position as Director of the Mainz Lung Center . His clinical and scientific interests focus on interstitial and rare lung diseases. He is conducting various research projects on comorbidities, epidemiology, biomarkers and diagnosis and therapy of interstitial lung diseases, and is engaged in educative events, e.g., organising again the next ERS school on ILDs in Mainz, Germany.
During the recent years, especially during the pandemic we have learned that international platform trials help to find solutions and answers to urgent questions in the medical field. Interstitial Lung Diseases are one of the prospering fields in pulmonary medicine which is very innovative and were in the recent past the advent of new therapies has changed the landscape for treatment of these diseases. But many unsolved questions, especially in fibrotic ILD still remain and need to be solved on an international basis urgently – and REMAP ILD has the greatest potential to foster clinical trials and development of new therapies in this area. Prof. Dr. Michael Kreuter
During the recent years, especially during the pandemic we have learned that international platform trials help to find solutions and answers to urgent questions in the medical field. Interstitial Lung Diseases are one of the prospering fields in pulmonary medicine which is very innovative and were in the recent past the advent of new therapies has changed the landscape for treatment of these diseases. But many unsolved questions, especially in fibrotic ILD still remain and need to be solved on an international basis urgently – and REMAP ILD has the greatest potential to foster clinical trials and development of new therapies in this area.
Prof. Dr. Michael Kreuter